Efficacy and Safety Study of SUNPG1623

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Active Psoriatic Arthritis

This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623

Inclusion Criteria:

• Subject has provided written informed consent
• Subject is ≥ 18 years of age at time of Screening
• Subject must be on stable dose of NSAID for ≥ 4 weeks prior to initiation of IMP
• Subject has a negative evaluation for TB within 4 weeks before initiating IMP
• Subject has a diagnosis of PsA (by the Classification of Psoriatic Arthritis [CASPAR] criteria) with symptoms present for at least 6 months.
• Subject has ≥ 3 tender and ≥ 3 swollen joints at Screening and Baseline.

Exclusion Criteria:

• Subject has a planned surgical intervention between Baseline and the Week 24 evaluation for a pretreatment condition
• Subject has an active infection or history of infections
• Subject has any concurrent medical condition or uncontrolled, clinically significant systemic disease
• Subject has a known history of infection with hepatitis B, hepatitis C, or human immunodeficiency virus